Compare Sana Biotechnology Inc (SANA) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs VNET Group Inc — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: VNET Group Inc is the larger of the two by market cap, and VNET Group Inc is more actively traded (4,955,295 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and VNET Group Inc for 16 Days on average.
| SANA | VNET | |
|---|---|---|
Market Cap | $836.71M | $1.47B |
Volume | 4,507,444 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $5.92 | $14.03 |
52-Week Low | $2.68 | $5.13 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $749.96M | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
VNET trades at $5.17, down 4.08% today, near 52-week lows. The stock is technically bearish with weak moving averages. Fundamentally, revenue grew to $9.95B in 2025, but net losses persist with a -22.18% margin. Recent news includes a strategic investment closing and a cooperation agreement with CATL.
Outlook remains challenged by losses and high leverage, though analyst consensus is moderately bullish. Key risks include negative cash flow and execution uncertainty. The stock offers speculative appeal if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
